The Richard N. Merkin Prize in Biomedical Technology recognizes pathbreaking technologies that are demonstrably improving human health and the key individuals who contributed to their development. The prize illuminates the important work taking place across multiple disciplines, and in doing so supports and inspires continued innovation.
The Merkin Prize has an intentional focus on real-world impact, and a goal of shining a light on novel technologies and how these advances are transforming health care. It is administered by the Broad Institute of MIT and Harvard. The prize annually celebrates a novel technology and recognizes the key contributors, including individuals and teams, from anywhere in the world with a cash award of $400,000.
Eligibility
Eligibility for the Merkin Prize extends to important, novel technologies that have had demonstrable real-world impact on human health, such as prevention, diagnosis, or treatment of disease, and the individuals and/or teams who were key contributors to their development.
Nominators may submit no more than two nominations per cycle. A nominator must be one or more individuals, not an institution or an organization. Submissions from nominators in any discipline and residing in any part of the world will be considered. For the full list of eligibility, please visit the Merkin Prize Eligibility Page.
More information including nomination instructions can be found on the Merkin Prize website. Nomination deadline is December 4, 2026 at 11:59pm ET.